You’ve likely heard that penny stocks are high-risk investments, and if so, you’ve heard right. However, a significant part ...

A New York federal judge has dismissed a $6.4 billion lawsuit against Bristol Myers Squibb, agreeing with counsel for the ...

For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow ...

District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol ...

As part of the deal, which could be worth $3.5bn, BMS will gain developmental support and therapeutic reagents from Prime ...

IGM has appointed ex-Bristol Myers Squibb & Co’s executive BMY Mary Beth Harler as the CEO. Chris Takimoto, Chief Medical ...

In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan ...

A New York federal judge dismissed allegations on Monday that Bristol Myers Squibb purposely delayed Breyanzi’s approval to ...

In an effort to expand its cash runway beyond 12 months, Prime Medicines has signed a deal with Bristol Myers Squibb worth a ...

Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by ...

Prime Medicine will partner with Bristol Myers Squibb (BMS) to develop and commercialize an unspecified number of reagents for ex vivo T-cell therapies through a collaboration that could generate more ...